Long Term: looking for an entry point on this beautiful stock

Novo Nordisk is one of the world leaders in the medical treatment of diabetes.

It also researches, develops and markets treatments for obesity. It is a fast-growing sector with the rise of fast food and the development of emerging countries.

However, the field is becoming more and more competitive, especially in the US, which has meant slower growth for the future of Novo Nordisk. Until now, she was considered a "cash cow".

Let's see if I can drink her milk :-)